It can be concluded that primary NSCLC cells are able to downregulate the expression of CD40, CD80, CD86, and HLA-DR on CD1c+ DCs after incubation with DCs derived from the same NSCLC patients. This evidence concerns the gene CD86 and non-small cell lung carcinoma.